Business Wire

New Research Concludes EU will Miss Climate Goals Unless Cleantech Innovation Is Scaled

23.3.2021 12:37:00 EET | Business Wire | Press release

Share

Newly-published research from Cleantech Group®, the global authority on clean technology innovation, with the support of Breakthrough Energy, found the EU’s venture capital investment into cleantech from 2011-2020 grew by a remarkable 7.5x to more than EUR 5 billion in 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005539/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

EU Cleantech Venture Capital Investment grew by 7.5x between 2011 and 2020 (Cleantech Group)

But research also discovered progress is concentrated on early-stage development and lacks scale-up investment and policy support. The EU attracted 23% of global cleantech seed-stage funding in 2020, but only 7% of global cleantech growth equity funding (compared to 54% for North America). The EU risks missing key climate targets by failing to scale clean technologies and letting promising innovators scale in North America and Asia instead.

Cleantech for Europe is a new initiative launched by Cleantech Group®, with the support of Breakthrough Energy, to help the EU lead the global clean transformation through targeted research and recommendations on EU cleantech investment and policy. The initiative connects EU policy makers to entrepreneurs and investors.

Its first position paper, published today, Making Fit for 55 a green demand shock to scale EU cleantech, analyses the EU cleantech landscape. It advocates for leveraging the EU’s upcoming Fit for 55 regulatory package to create leadership in five key innovation sectors: green hydrogen, green steel, low-carbon construction materials, sustainable aviation and soil carbon. The paper makes the case for a green demand shock that would pull EU innovators to continental scale and maximize climate impact.

“The EU’s climate future is at a crossroads. Deploying mature technologies such as solar and wind can only take us halfway. To lead the race to net zero, and gain a competitive advantage for decades, the EU needs a green demand shock to scale early-stage clean technologies” said Jules Besnainou, Director, Cleantech Group.

“With the forthcoming ‘Fit for 55’ package, the EU will update almost all of its energy and climate legislation, changing the policy framework for a long time to come. With investment cycles averaging 25 years, what happens in 2050 is essentially being decided today. The stakes couldn’t be higher as only a new generation of clean technologies can lead Europe towards climate neutrality. That is why this study sheds light on persistent challenges in the European innovation ecosystem that urgently need to be addressed – from lack of growth equity and weak demand signals for green products to poor exit routes for successful entrepreneurs” said Ann Mettler, Vice President, Europe, Breakthrough Energy.

Link to research: https://www.cleantechforeurope.com/

About Cleantech Group
At Cleantech Group, we provide research, consulting and events to catalyze opportunities for sustainable growth powered by innovation. We bring clients access to the trends, companies and people shaping the future and the customized advice and support businesses need to engage external innovation. Industries are undergoing definitive transitions toward a more digitized, de-carbonized and resource-efficient industrial future. At every stage from initial strategy to final deals, our services bring corporate change makers, investors, governments and stakeholders from across the ecosystem, the support they need to thrive in this fast-arriving and uncertain future.

The company was established in 2002 and is headquartered in San Francisco with people based in London, Paris and Boston.

About Breakthrough Energy
Founded by Bill Gates, Breakthrough Energy is dedicated to helping humanity avoid a climate disaster. Through investment vehicles, philanthropic programs, policy advocacy, and other activities, we’re committed to scaling the technologies we need to reach net-zero emissions by 2050. For more information about Breakthrough Energy visit breakthroughenergy.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jules Besnainou
Director, Cleantech Group
hello@cleantechforeurope.com
+33 6 23 12 00 08

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye